多中心、开放标签、IV期随机试验检验膀胱切除术后输尿管支架取出时个体化靶向抗生素预防优于经验性预防:REINFORCE试验研究方案
本研究为多中心、开放标签、优效性随机临床试验,采用组序贯设计,计划纳入248例膀胱切除术后患者,1:1随机分配至输尿管支架取出当日接受标准治疗 pivmecillinam 400 mg 每日三次或依据术后尿液微生物群靶向抗生素治疗,主要终点为术后90天感染相关再入院率,假设从29%降至14%。
要点
- 比较膀胱切除术后输尿管支架取出时靶向抗生素与经验性 pivmecillinam 对感染相关再入院的影响。
- 主要终点为术后90天感染相关再入院率,假设从29%降至14%,需治疗人数为6。
- 计划纳入248例患者,采用组序贯设计,在入组50%时按预设规则进行中期分析以决定是否提前终止。
核心结论
- 本方案提出首个随机临床试验,检验个体化靶向抗生素能否降低膀胱切除术后感染风险,结果可能改善该脆弱患者群体的康复并促进抗生素管理。
研究设计与样本
- 多中心、开放标签、优效性随机临床试验,采用组序贯设计,1:1随机分配,计划纳入248例患者。
主要发现
- 样本量基于感染相关再入院率从29%绝对降至14%的假设,对应需治疗人数为6以减少一次再入院。
关键数值与推荐
- 干预组在输尿管支架取出当日接受针对术后尿液样本中所鉴定微生物群的抗生素治疗。
- 对照组在输尿管支架取出当日接受标准治疗 pivmecillinam 400 mg 晨、午、晚口服,单日疗程。
- 主要终点为术后90天感染相关再入院率。
- 次要终点包括并发症和再入院率、存活且不在医院的天数、生活质量、尿液和血液微生物分离及抗菌药物敏感性分析。
- 在入组50%时按预设规则进行中期分析,允许提前终止。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the first months after cystectomy, the most frequent cause of readmission is infection from the urinary tract. Nonetheless, current guidelines are unable to provide evidence-based recommendations on preventative measures and, as a result, antibiotic prophylaxis varies across surgical centres. Most centres in Denmark administer empiric antibiotic prophylaxis at ureteral stent removal after cystectomy, where infection rates peak. However, data indicates that the postoperative urinary microbiota is composed of a wide range of bacteria, suggesting that the patients may benefit from an individualised approach. This trial aims to test whether targeted postoperative antibiotic prophylaxis can reduce infection-related readmissions after cystectomy compared to the current empiric approach. METHODS: We present a multicentre, open-label, superiority, randomised clinical trial using a group-sequential design. Participants will be randomly assigned with a 1:1 allocation ratio to receive one of two orally administered single-day antibiotic treatments on the day of ureteral stent removal: (a) standard-of-care pivmecillinam 400 mg morning, noon, and evening or (b) antibiotics targeted to the microbiota identified in a postoperative urine sample. The primary endpoint is the infection-related readmission rate after 90 postoperative days. Secondary endpoints include complication and readmission rates, days alive and out of hospital, quality of life, and microbiological isolates in the urine and blood and antimicrobial susceptibility analyses. A total of 248 patients are planned to be enrolled. The sample size is based on a hypothesised absolute risk reduction in the infection-related readmission rate from 29 to 14%, corresponding to a number needed to treat of six to reduce one hospital readmission. A group-sequential design is proposed to allow for early stopping at interim analysis after 50% enrolment based on predefined rules. DISCUSSION: Responsible use of antibiotics is gaining increasing importance globally, and proper prophylactic strategies amongst high-risk patients are essential to avoid hospital admissions with administration of broad-spectrum agents. In this protocol, we present the first randomised clinical trial testing whether individualised targeted antibiotics can reduce the risk of infections after cystectomy. Results of the trial may improve recovery for this vulnerable patient group, while also potentially improving antibiotic stewardship. TRIAL REGISTRATION: EU trial number 2024-514312-27-00. Registered on December 10, 2024. CLINICALTRIALS: gov NCT06709196. Registered on November 27, 2024.
引用
- Vejlgaard M, Stroomberg HV, Ynddal MS, et al. Multicentre, open-label, phase IV, randomised trial testing superiority of individualised targeted antibiotic prophylaxis over empiric prophylaxis at ureteral stent removal following cystectomy: study protocol for the REINFORCE trial. Trials. 2025. PMID: 40722189. doi:10.1186/s13063-025-08981-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。